A case report of primary pericardial malignant mesothelioma treated with pemetrexed and cisplatin

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Primary pericardial malignant mesothelioma (PPM) is a very rare malignancy, with an incidence of less than 0.002% and represents less than 5% of all mesotheliomas. The cause of pericardial mesothelioma is uncertain that differ from pleural mesothelioma which is associated with asbestos exposure. This malignancy is terribly aggressive and has very poor prognosis with less than six months of overall survival. We present a case of a 71-year-old woman who was diagnosed with cardiac tamponade caused by PPM and received chemotherapy with pemetrexed and cisplatin for six months. During two years she was alive without disease progression. To better understand the clinical, pathologic features and treatment outcome of this entity, we reviewed 23 cases described in the English literature from 2009, together with our case, provided a total of 24 cases. Based on this review, we suggest that PPM must be considered in patients who have unexplained massive pericardial effusion and recommend chemotherapy with pemetrexed and cisplatin for the better outcome of PPM.

Original languageEnglish
Pages (from-to)1879-1884
Number of pages6
JournalJournal of Korean Medical Science
Volume32
Issue number11
DOIs
Publication statusPublished - 2017 Nov 1

Fingerprint

Pemetrexed
Cisplatin
Mesothelioma
Literature
Drug Therapy
Cardiac Tamponade
Pericardial Effusion
Asbestos
Disease Progression
Neoplasms
Survival
Malignant Mesothelioma
Incidence

Keywords

  • Cardiac tamponade
  • Cisplatin
  • Pemetrexed
  • Primary pericardial mesothelioma

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{bd3366cb70b44ecf9be3a3a8c11eb425,
title = "A case report of primary pericardial malignant mesothelioma treated with pemetrexed and cisplatin",
abstract = "Primary pericardial malignant mesothelioma (PPM) is a very rare malignancy, with an incidence of less than 0.002{\%} and represents less than 5{\%} of all mesotheliomas. The cause of pericardial mesothelioma is uncertain that differ from pleural mesothelioma which is associated with asbestos exposure. This malignancy is terribly aggressive and has very poor prognosis with less than six months of overall survival. We present a case of a 71-year-old woman who was diagnosed with cardiac tamponade caused by PPM and received chemotherapy with pemetrexed and cisplatin for six months. During two years she was alive without disease progression. To better understand the clinical, pathologic features and treatment outcome of this entity, we reviewed 23 cases described in the English literature from 2009, together with our case, provided a total of 24 cases. Based on this review, we suggest that PPM must be considered in patients who have unexplained massive pericardial effusion and recommend chemotherapy with pemetrexed and cisplatin for the better outcome of PPM.",
keywords = "Cardiac tamponade, Cisplatin, Pemetrexed, Primary pericardial mesothelioma",
author = "Kim, {Jung Sun} and Lim, {Sang Yeob} and Jinwook Hwang and Kang, {Eun Joo} and Choi, {Yoon Ji}",
year = "2017",
month = "11",
day = "1",
doi = "10.3346/jkms.2017.32.11.1879",
language = "English",
volume = "32",
pages = "1879--1884",
journal = "Journal of Korean Medical Science",
issn = "1011-8934",
publisher = "Korean Academy of Medical Science",
number = "11",

}

TY - JOUR

T1 - A case report of primary pericardial malignant mesothelioma treated with pemetrexed and cisplatin

AU - Kim, Jung Sun

AU - Lim, Sang Yeob

AU - Hwang, Jinwook

AU - Kang, Eun Joo

AU - Choi, Yoon Ji

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Primary pericardial malignant mesothelioma (PPM) is a very rare malignancy, with an incidence of less than 0.002% and represents less than 5% of all mesotheliomas. The cause of pericardial mesothelioma is uncertain that differ from pleural mesothelioma which is associated with asbestos exposure. This malignancy is terribly aggressive and has very poor prognosis with less than six months of overall survival. We present a case of a 71-year-old woman who was diagnosed with cardiac tamponade caused by PPM and received chemotherapy with pemetrexed and cisplatin for six months. During two years she was alive without disease progression. To better understand the clinical, pathologic features and treatment outcome of this entity, we reviewed 23 cases described in the English literature from 2009, together with our case, provided a total of 24 cases. Based on this review, we suggest that PPM must be considered in patients who have unexplained massive pericardial effusion and recommend chemotherapy with pemetrexed and cisplatin for the better outcome of PPM.

AB - Primary pericardial malignant mesothelioma (PPM) is a very rare malignancy, with an incidence of less than 0.002% and represents less than 5% of all mesotheliomas. The cause of pericardial mesothelioma is uncertain that differ from pleural mesothelioma which is associated with asbestos exposure. This malignancy is terribly aggressive and has very poor prognosis with less than six months of overall survival. We present a case of a 71-year-old woman who was diagnosed with cardiac tamponade caused by PPM and received chemotherapy with pemetrexed and cisplatin for six months. During two years she was alive without disease progression. To better understand the clinical, pathologic features and treatment outcome of this entity, we reviewed 23 cases described in the English literature from 2009, together with our case, provided a total of 24 cases. Based on this review, we suggest that PPM must be considered in patients who have unexplained massive pericardial effusion and recommend chemotherapy with pemetrexed and cisplatin for the better outcome of PPM.

KW - Cardiac tamponade

KW - Cisplatin

KW - Pemetrexed

KW - Primary pericardial mesothelioma

UR - http://www.scopus.com/inward/record.url?scp=85030179614&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030179614&partnerID=8YFLogxK

U2 - 10.3346/jkms.2017.32.11.1879

DO - 10.3346/jkms.2017.32.11.1879

M3 - Article

C2 - 28960045

AN - SCOPUS:85030179614

VL - 32

SP - 1879

EP - 1884

JO - Journal of Korean Medical Science

JF - Journal of Korean Medical Science

SN - 1011-8934

IS - 11

ER -